Clinical Trial Update: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tirzepatide (LY3298176) to semaglutide as add-on to metformin in type 2 diabetes completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tirzepatide (tirzepatide)
• semaglutide (semaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2022-02-14